Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07465224 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

StatusRecruiting
PhasePhase 2
Started2026-01-15
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 40% 40 → 24 participants
See other at-risk trials from Alnylam Pharmaceuticals

Amendment history

2026-08-11
Study Status v5
Re-verified, no change to tracked fields
2026-07-22
Study Status, Study Design, Eligibility v4
Enrollment reduced: 40 → 24 participants
Eligibility criteria+95 characters
Inclusion Criteria: Is an adult patient with a confirmed diagnosis of T2DM Has a body mass index (BMI) of ≥2523 kg/m^2 andto <≤39.9 kg/m^2 Has a hemoglobin A1c (HbA1c) ≥6.5% to <10.5% Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i) Exclusion Criteria: Has any clinically significant concomit [...]
2026-06-10
3 amendments v1-v3
3 re-verifications since 2026-04-16, no change to tracked fields
2026-03-06
Original filing
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Trial Details
NCT Number NCT07465224
Lead Sponsor Alnylam Pharmaceuticals
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 24 participants
Start Date 2026-01-15
Primary Completion 2027-05-28 (estimated)
Study Completion 2027-05-28 (estimated)
Updated on ClinicalTrials.gov 2026-09-16